Gene Editing Enzymes

Gene Editing Enzymes

Nucleases for Research and Clinical Applications

There are many commercial nuclease suppliers for basic research and academic purposes. But your goals and needs are different. You aspire to utilize CRISPR gene editing for research or therapeutic purposes and need a product that is going to be available under the appropriate quality systems (research grade, ISO 13485, or full GMP) as you progress.

Aldevron manufactures and stocks nucleases that can eliminate the need for custom manufacturing runs, as your program moves towards commercialization.

Product Description Stocked at Research Grade cGMP Pack Sizes Drug Master File on File
Eureca-V™ Nuclease* Wild-type MAD7™ ® Type-V nuclease with pass-through licensing* Yes Coming Soon No
SpyFi™ Cas9 Nuclease High fidelity nuclease with less off-target activity Yes Yes Yes
SpCas9 Nuclease Wild-type SpCas9 Yes Yes Yes
AsCas12a Nuclease Wild-type AsCas12a Yes No No
SaCas9 Nuclease Wild-type SaCas9 Yes No No

*Licensed from Inscripta®

Ordering Information

Product Small Size Catalog Number Large Sizes Catalog Number
Eureca-V™ Nuclease 1MG 9300-1MG 5MG 9300-5MG
SpyFi™ Cas9 Nuclease 0.25MG 9214-0.25MG 5MG 9214-5MG
SpCas9 Nuclease 0.25MG 9212-0.25MG 5MG 9212-5MG
AsCas12a Nuclease 0.25MG 9213-0.25MG 5MG 9213-5MG
SaCas9 Nuclease 0.25MG 9218-0.25MG 5MG 9218-5MG
GMP-Manufactured Nucleases
SpyFi™ Cas9 Nuclease – GMP 1MG 9216-0.1ML 10MG 9216-1ML
SpCas9 Nuclease 1MG 9211-0.1ML 10MG 9211-1ML

Don’t See What You Need?

Aldevron offers custom manufacture of unique Cas enzyme configurations including dCas9 fusions, nickases, Cas9 variants and non-Cas9 nucleases. For more information visit our Custom Protein Manufacturing page or contact our Custom Nuclease Services group.

Ribonucleoprotein Production**

Aldevron offers an RNP service to streamline transforming your CRISPR reagents into therapies. Working with your unique guide RNAs, we’ve defined: the optimal conditions for complexing, characterizing, and storing CRISPR RNPs created with Aldevron research and GMP-grade CRISPR/Cas9 proteins. Our proprietary release panels are compliant with 21CFR210-211 and designed to meet current draft guidance from the FDA regarding gene editing, which provides consistency of the final product. Learn More.

**Aldevron provides RNPs only to customers who are duly licensed, including to make and have made RNPs, for their intended use.
Scientific Publications

Publications featuring other Aldevron Nuclease’s

  • High-efficiency nonviral CRISPR/cas9-mediated gene editing of human T cells using plasmid donor DNA

This publication showed improved CAR-T knock-in efficiency, reduced cell death, and an improved T cell phenotype for CAR-T cell therapies using Nanoplasmid compared to conventional plasmids and linear DNA as an HDR template. Experiments are conducted with SpyFi Cas9 Nucelase.

Oh SA, Senger K, Madireddi S, Akhmetzyanova I, Ishizuka IE, Tarighat S, et al. High-efficiency nonviral CRISPR/cas9-mediated gene editing of human T cells using plasmid donor DNA. Journal of Experimental Medicine. 2022;219(5).

  • Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells

This paper showed GMP-compliant method to manufacture CRISPR gene-edited VSTs that are unaffected by glucocorticoid treatment. These CRISPR-edited VSTs have comparable potency to non-gene edited VSTs but could be co-administered to patients with steroids. The GMP manufacturing workflow applies Aldevron SpyFi™ Cas9 Nuclease as the gene editing reagent due to its high on-target editing efficiency and greatly reduced off-target editing in comparison to wild-type SpCas9.

Basar, R., Daher, M., Uprety, N., Gokdemir, E., Alsuliman, A., Ensley, E., Ozcan, G., Mendt, M., Hernandez Sanabria, M., Kerbauy, L. N., Nunez Cortes, A. K., Li, L., Banerjee, P. P., Muniz-Feliciano, L., Acharya, S., Fowlkes, N. W., Lu, J., Li, S., Mielke, S., Kaplan, M., … Rezvani, K. (2020). Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood advances, 4(14), 3357–3367.


Discuss your project with an expert

Get in Touch